http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Expro Ltd Schedules Second Quarter 2026 Earnings Release and Conference Call
-
RWB Completes Transformational Florida Divestiture, Expected to Eliminate Over $123 Million of Liabilities and Significantly Strengthen the Company’s Balance Sheet
-
Carolina Rush Appoints Patrick Quigley Vice President of Exploration, Grants RSUs and Options, Extends Warrants
-
Personalis wins UKCA mark for cancer detection test in Great Britain
-
Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain
-
ESET Research discovers vulnerable UEFI shims undermining devices’ Secure Boot
-
Hummingbird Bioscience Wins APAC Trailblazer Award at 2026 Nebius AI Discovery Awards
-
BeritaWire Proves Media Exposure Doesn’t Have to Come With an Enterprise Price Tag
-
Mesoblast reaches 300-patient enrollment in back pain Phase 3 trial
-
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
-
Arctic Fox Lithium Approved for Trading on the OTCQB Venture Market and Announces DTC Eligibility
-
Empire State Building launches family bundle with up to 20% off tickets
-
Empire State Building Observation Deck Debuts New Family Bundle Ticket Options
-
CORRECTION -- HII
-
CORRECTION -- HII
-
Media Invited to Visit HII’s Newport News Shipbuilding – Charleston Operations
-
KFC® Answers Fans' Calls (and Comments) With the Return of Popcorn Chicken, Reigniting Obsession Nationwide
-
Next Bridge Hydrocarbons Releases Latest Correspondence Attempt with SEC Officials
-
Yaamava' Marks 40 Years with Collector Cars, Michelin-Starred Dining and Major Concerts
-
MacKay Municipal Managers™ Provides Mid-Year Scorecard Update to Top Five Municipal Market Insights for 2026
-
THIRDREALITY Launches ZW1 Zigbee Smart Wall Outlet with Independent Control for Both Receptacles
-
IPANY Partners With ExtensisHR to Deliver Enterprise-Level Benefits and HR Solutions to New York Providers
-
ShamlaTech Launches AI Agent for Shopify, WooCommerce, and Magento Stores in the U.S.
-
Assetara Launches Full-Featured AI Investment Ecosystem with ASRA Token, Smart Staking, and 30-Tier Level System
-
RedChip Adds Optex Systems to July 16 Virtual Investor Conference
-
Cellares and Sonoma Biotherapeutics Collaborate to Automate Manufacturing of SBT-77-7101 Engineered Treg Cell Therapy on the Cell Shuttle® Platform
-
RedChip to Host Exclusive Live Webinar and Investor Q&A with The Metals Company on July 15, 2026
-
Northstar Receives Initial $627,663 Digital Co-Investment Payment Provides Cam Copper Surgical Mining Project Update
-
Guardforce AI to Present Live, Answer Questions, at Skyline Signature Series™ on July 22, 2026, at 11:00 AM ET
-
MNA: Brigham Nurses Return to Patients Following Historic Strike and Lockout; Fight for Fair Contracts and Safe Patient Care Continues
-
Victory Capital reports $346.1 billion in total client assets for June
-
Lineage Cell Therapeutics updates COR1 corneal cell therapy program
-
Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease
-
Slate Grocery REIT to Release Second Quarter 2026 Financial Results
-
Hypha Labs (OTCQB:FUNI) Sees State-by-State Psilocybin Reform Creating the Next Major Growth Opportunity
-
Victory Capital Reports June 2026 Total Client Assets
-
Ionis starts Phase 1-2 trial of ION337 for Dravet syndrome
-
VERAXA Biotech partners with Ardigen on AI drug discovery for cancer
-
Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
-
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
-
Galway Metals Reports Updated Clarence Stream Mineral Resource Estimate
-
Q32 Bio reports Phase 2a trial results for alopecia areata drug
-
Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
-
Carolina Rush Reports Final Results of Initial Brewer Porphyry Drill Program, Intersects Near-Mine Epithermal Gold-Copper Mineralization
-
Zip Opens New York City Hub, Plans to Double Local Team
-
BeritaWire Adapts to a News Cycle That No Longer Waits for Traditional PR
-
India's Finest. World's Best. The Leela Ranked the World's #2 Best Hotel Brand in the Travel + Leisure World's Best Awards 2026 Survey
-
Garuda Indonesia Strengthens Service Transformation with Piece-based Checked Baggage Policy
-
Celea Therapeutics begins Phase 3 trial of deupirfenidone for IPF
-
PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
